Elisabetta Poluzzi

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 22

Top Venues

Drug safety

Expert opinion on drug safety

PloS one

Expert opinion on pharmacotherapy

University of Bologna

University of Bologna (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Bologna Sep 15 2015

Italy

Associate Professor of Pharmacology :: Department of Medical and Surgical Sciences

Education History

University of Bologna Apr 05 2004

Italy

PHD :: Department of Medical and Surgical Sciences

Publications

Carlotta Lunghi, Marco Domenicali, Stefano Vertullo, Emanuel Raschi, Fabrizio de Ponti, Graziano Onder, Elisabetta Poluzzi
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals. Drug safety (2024)
Elisabetta Poluzzi, Emanuel Raschi, Carlotta Lunghi, Alice Bertuccio, Andreas Eleftheriou, Fabrizio de Ponti
Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward. British journal of clinical pharmacology (2024)
Michele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, Manfred Hauben
The evolving role of disproportionality analysis in pharmacovigilance. Expert opinion on drug safety 23 (8) (2024)
Michele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, Manfred Hauben
The evolving role of disproportionality analysis in pharmacovigilance. Expert opinion on drug safety (2024)
Valentina Giunchi, Michele Fusaroli, Manfred Hauben, Emanuel Raschi, Elisabetta Poluzzi
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach. Drug safety (2023)
Michele Fusaroli, Arndis Simonsen, Stephanie A Borrie, Daniel M Low, Alberto Parola, Emanuel Raschi, Elisabetta Poluzzi, Riccardo Fusaroli
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System. Journal of speech, language, and hearing research : JSLHR (2023)
Emanuel Raschi, Michele Fusaroli, Valentina Giunchi, Andrea Repaci, Carla Pelusi, Veronica Mollica, Francesco Massari, Andrea Ardizzoni, Elisabetta Poluzzi, Uberto Pagotto, Guido Di Dalmazi
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System. Cancers 14 (19) (2022)
Carlotta Lunghi, Caterina Trevisan, Michele Fusaroli, Valentina Giunchi, Emanuel Raschi, Elisa Sangiorgi, Marco Domenicali, Stefano Volpato, Fabrizio de Ponti, Elisabetta Poluzzi
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People. Pharmaceuticals (Basel, Switzerland) 15 (8) (2022)
Iva Selke Krulichová, Gisbert W Selke, Marion Bennie, Mohammadhossein Hajiebrahimi, Fredrik Nyberg, Jurij Fürst, Kristina Garuolienė, Elisabetta Poluzzi, Juraj Slabý, Corinne Zara Yahni, Mattia Altini, Maria Pia Fantini, Václav Kočí, Stuart McTaggart, Caridad Pontes, Chiara Reno, Simona Rosa, Marta Turu Pedrola, Mitja Udovič, Björn Wettermark
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study. Pharmacoepidemiology and drug safety 31 (10) (2022)
Michele Fusaroli, Valentina Isgrò, Paola Maria Cutroneo, Carmen Ferrajolo, Valentina Cirillo, Francesca Del Bufalo, Emanuel Raschi, Elisabetta Poluzzi, Gianluca Trifirò
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug safety 45 (8) (2022)
Emanuel Raschi, Igor Diemberger, Mario Sabatino, Elisabetta Poluzzi, Fabrizio de Ponti, Luciano Potena
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert opinion on pharmacotherapy 23 (3) (2022)
Manuela Casula, Federica Galimberti, Marica Iommi, Elena Olmastroni, Simona Rosa, Mattia Altini, Alberico Luigi Catapano, Elena Tragni, Elisabetta Poluzzi
Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies. International journal of environmental research and public health 19 (19) (2022)
Milo Gatti, Michele Fusaroli, Emanuel Raschi, Ugo Moretti, Elisabetta Poluzzi, Fabrizio de Ponti
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. Expert opinion on drug safety 20 (11) (2021)
Milo Gatti, Michele Fusaroli, Emanuel Raschi, Irene Capelli, Elisabetta Poluzzi, Fabrizio de Ponti
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. Journal of nephrology (2021)
Milo Gatti, Elisabetta Poluzzi, Fabrizio de Ponti, Emanuel Raschi
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. Drug safety 43 (12) (2021)
Carlotta Lunghi, Ippazio Cosimo Antonazzo, Sofia Burato, Emanuel Raschi, Violetta Zoffoli, Emanuele Forcesi, Elisa Sangiorgi, Marco Menchetti, Pasquale Roberge, Elisabetta Poluzzi
Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study. Neuropsychiatric disease and treatment 16 (2020)
Marica Iommi, Simona Rosa, Michele Fusaroli, Paola Rucci, Maria Pia Fantini, Elisabetta Poluzzi
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions. PloS one 15 (10) (2020)
Emanuel Raschi, Gian Poalo Fadini, Igor Diemberger, Elisabetta Poluzzi, Fabrizio de Ponti
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? Expert opinion on pharmacotherapy 22 (5) (2020)
Lorenzo Berardi, Ippazio Cosimo Antonazzo, Carlo Piccinni, Emanuel Raschi, Emanuele Forcesi, Angelo Fioritti, Domenico Berardi, Fabrizio De Ponti, Antonella Piazza, Elisabetta Poluzzi
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. PloS one 14 (2) (2019)
Ippazio Cosimo Antonazzo, Emanuel Raschi, Luca Vignatelli, Elisa Baldin, Trond Riise, Roberto D'Alessandro, Fabrizio De Ponti, Elisabetta Poluzzi
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. Drug safety 40 (9) (2018)
Elisabetta Poluzzi, I Diemberger, M De Ridder, A Koci, M Clo, A Oteri, S Pecchioli, I Bezemer, T Schink, S Pilgaard Ulrichsen, G Boriani, M C J Sturkenboom, F De Ponti, G Trifirò
Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. European journal of clinical pharmacology 73 (11) (2017)
Elisabetta Poluzzi, Emanuel Raschi, Igor Diemberger, Fabrizio De Ponti
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. Drug safety 40 (6) (2017)

Elisabetta Poluzzi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Elisabetta Poluzzi